Your session is about to expire
← Back to Search
Other
Red-light Therapy for Near-sightedness
N/A
Recruiting
Led By Julius Oatts, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial showed that 3 minutes of low-level red-light technology twice a day can control 87.7% of myopia progression and 76.8% of axial length elongation. This could be a potential global solution for myopia control.
Who is the study for?
This trial is for kids aged 8-13 with near-sightedness (myopia) between -1.00 and -5.00 diopters, less than 1.50 diopters of anisometropia, and up to 2.50 diopters of astigmatism who speak English and have good corrected vision. It's not for those with eye abnormalities, previous myopia treatments, or severe disabilities.
What is being tested?
The study tests a low-level red-light therapy device as a treatment for myopia in children from diverse backgrounds by having them undergo short light sessions twice daily to see if it can control the progression of their near-sightedness effectively.
What are the potential side effects?
While specific side effects are not listed here, similar light therapies have been associated with minimal risks such as mild discomfort or temporary visual disturbances.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Axial Length (AL) (mm) at Baseline
Axial Length (AL) (mm) at Month 1
Axial Length (AL) (mm) at Month 3
+2 moreSecondary study objectives
Anterior Chamber Depth (ACD) at Baseline
Anterior Chamber Depth (ACD) at Month 1
Anterior Chamber Depth (ACD) at Month 3
+32 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Low Level Red Light Treatment ArmExperimental Treatment1 Intervention
On top of wearing single vision spectacles, subjects in the intervention group will receive low-level red light treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours.
Group II: Control Treatment ArmActive Control1 Intervention
Subjects in the control group will wear single vision spectacles.
Find a Location
Who is running the clinical trial?
University of MelbourneOTHER
182 Previous Clinical Trials
1,282,160 Total Patients Enrolled
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,860 Total Patients Enrolled
Julius Oatts, MDPrincipal InvestigatorUniversity of California, San Francisco
3 Previous Clinical Trials
190 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have received treatments for myopia control in the past.My doctor thinks I shouldn't join due to severe health or cognitive issues.My parents did not sign the consent form for me.I do not have eye or other health issues that would stop me from doing study tasks.I have crossed eyes or vision problems in both eyes.I am between 8 and 13 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Low Level Red Light Treatment Arm
- Group 2: Control Treatment Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.